Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine C Park

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
International Journal of Radiation Biology|December 7, 2007
beta1 integrin as a molecular therapeutic targetNils Cordes, Catherine C Park
International Journal of Radiation Oncology, Biology, Physics|July 1, 2022
Contralateral Disease Begets Contralateral TreatmentNicolas D Prionas, Catherine C Park
Seminars in Radiation Oncology|June 10, 2022
Seminars in Radiation Oncology-Breast CancerCatherine C Park, Jean L Wright
Cancer Research|April 12, 2013
NF-κB regulates radioresistance mediated by β1-integrin in three-dimensional culture of breast cancer cellsKazi Mokim Ahmed, Hui Zhang, Catherine C Park
International Journal of Radiation Oncology, Biology, Physics|August 12, 2008
High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancerCatherine C Park, James Rembert, Karen Chew, et al.
International Journal of Radiation Biology|November 10, 2009
beta1 integrin targeting to enhance radiation therapyJin-Min Nam, Yoonsun Chung, Howard C Hsu, et al.
Cancer Research|June 3, 2010
Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectinJin-Min Nam, Yasuhito Onodera, Mina J Bissell, et al.
Cancer Research|May 7, 2013
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastomaW Shawn Carbonell, Michael DeLay, Arman Jahangiri, et al.
Breast Cancer Research and Treatment|August 25, 2009
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironmentBritta Weigelt, Alvin T Lo, Catherine C Park, et al.
Cancer Research|June 4, 2008
Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenograftsCatherine C Park, Hui J Zhang, Evelyn S Yao, et al.
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
International Journal of Radiation Biology|December 7, 2007
beta1 integrin as a molecular therapeutic targetNils Cordes, Catherine C Park
International Journal of Radiation Oncology, Biology, Physics|July 1, 2022
Contralateral Disease Begets Contralateral TreatmentNicolas D Prionas, Catherine C Park
Seminars in Radiation Oncology|June 10, 2022
Seminars in Radiation Oncology-Breast CancerCatherine C Park, Jean L Wright
Cancer Research|April 12, 2013
NF-κB regulates radioresistance mediated by β1-integrin in three-dimensional culture of breast cancer cellsKazi Mokim Ahmed, Hui Zhang, Catherine C Park
International Journal of Radiation Oncology, Biology, Physics|August 12, 2008
High mammographic breast density is independent predictor of local but not distant recurrence after lumpectomy and radiotherapy for invasive breast cancerCatherine C Park, James Rembert, Karen Chew, et al.
International Journal of Radiation Biology|November 10, 2009
beta1 integrin targeting to enhance radiation therapyJin-Min Nam, Yoonsun Chung, Howard C Hsu, et al.
Cancer Research|June 3, 2010
Breast cancer cells in three-dimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectinJin-Min Nam, Yasuhito Onodera, Mina J Bissell, et al.
Cancer Research|May 7, 2013
β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastomaW Shawn Carbonell, Michael DeLay, Arman Jahangiri, et al.
Breast Cancer Research and Treatment|August 25, 2009
HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironmentBritta Weigelt, Alvin T Lo, Catherine C Park, et al.
Cancer Research|June 4, 2008
Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenograftsCatherine C Park, Hui J Zhang, Evelyn S Yao, et al.
Pageof 4